allogeneic CAR T cell therapy (Poseida Therapeutics)

N/A

Report date: 2022/08/09 13:54:16

Base Information

Drug Nameallogeneic CAR T cell therapy (Poseida Therapeutics)
Drug Alias Nameallogeneic CAR T cell therapies - Poseida Therapeutics/Rocheallogeneic CAR T cell therapies
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPoseida Therapeutics IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPoseida Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A